Previous 10 | Next 10 |
Guardion Health Sciences (NASDAQ:GHSI) +53%. RISE Education Cayman (NASDAQ:REDU) +20% on receipt of prelim non-bidding proposal to acquire all company assets Kaival Brands Innovations (NASDAQ:KAVL) +25% FDA enters administrative stay of Bidi Vapor's marketing denial order for i...
HOUSTON, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that the U.S. Food ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioPath (NASDAQ: BPTH ) stock is soaring higher on Tuesday after revealing an update on its Investigational New Drug (IND) application for BP1002. Source: CI Photos / Shutterstock.com The U.S. Food and Drug Ad...
Gainers: Takung Art (NYSE:TKAT) +48%. Triple-S Management (NYSE:GTS) +45%. KLX Energy (NASDAQ:KLXE) +25%. New Oriental Education (NYSE:EDU) +26%. SkyWater Technology (NASDAQ:SKYT) +25%. Sentage (NASDAQ:SNTG) +24%. Bio-Path Holdings (NASDAQ:BPTH) +20%. TuSimple (NASDAQ:TSP) +20%. CynergisTek (...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips PolarityTE (NASDAQ: PTE ) stock is taking a beating on Tuesday after the biotechnology company got an update from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug Application (IND). Sour...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips A new biopharma play just popped onto investors’ radars this morning. The Bio-Path (NASDAQ: BPTH ) camp is exciting shareholders and spurring a vast influx of trading volume today. The company is reporting a po...
Gainers: Triple-S Management (NYSE:GTS) +45%, Bio-Path (NASDAQ:BPTH) +21%, Reviva Pharmaceuticals (NASDAQ:RVPH) +21%, XTL Biopharmaceuticals (NASDAQ:XTLB) +13%, Protara Therapeutics (NASDAQ:TARA) +12%. Losers: Theravance Biopharma (NASDAQ:TBPH) ...
Triple-S Management (NYSE:GTS) +44% to be acquired by GuideWell in an all-cash deal worth $900 million Bio-Path (NASDAQ:BPTH) +32% on FDA clearance of BP1002 application in acute myeloid leukemia Cara Therapeutics (NASDAQ:CARA) +21% and Vifor Pharma announce U.S. FDA ...
HOUSTON, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that the U.S. Food ...
Bio-Path Holdings, Inc. (BPTH) Q2 2021 Earnings Conference Call August 13, 2021 08:30 AM ET Company Participants Peter Nielsen - President, CEO and CFO Anthony Price - SVP of Finance, Accounting and Administration Will O’Connor - Stern IR Conference Call Participants Yi Chen - H.C. Wai...
News, Short Squeeze, Breakout and More Instantly...
Bio-Path Holdings Inc. Company Name:
BPTH Stock Symbol:
NASDAQ Market:
Bio-Path Holdings Inc. Website:
Marks Meaningful Progress Across Key Clinical Trials in Multiple Cancer Indications Completes Development of Oncology Molecular Biomarkers and Prepares for Preclinical Obesity Studies HOUSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnolog...
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...